The health-related quality of life of drug-resistant tuberculosis patients receiving treatment in Botswana.

Background: Drug-resistant tuberculosis (DR-TB) poses a significant global health challenge and requires treatment with potentially toxic second-line anti-TB drugs. Assessing the health-related quality of life (HRQoL) of DR-TB patients is crucial, given the impact of disease and treatment on their well-being. This study aimed to evaluate HRQoL among DR-TB patients undergoing treatment in Botswana and identify predictors of variability during the treatment period.